sponsored
PatientsVille.com Logo

PatientsVille

Adenosquamous Medical Research Studies

Up-to-date List of Adenosquamous Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Adenosquamous Medical Research Studies

Rank Status Study
1 Not yet recruiting ADXS11-001 High Dose HPV+ Cervical Cancer
Conditions: Effects of Immunotherapy;   Metastatic/Recurrent Cervical Cancer;   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Biological: ADXS11-001
Outcome Measures: Number of patients with dose-limiting toxicities, as assessed by CTCAE v 4.0;   Frequency and severity of adverse effects as assessed by CTCAE v 4.0;   Proportion of patients who survive for at least 12 months;   Distribution of progression-free survival;   Changes in clinical immunology based upon serum;   Proportion of patients who have objective tumor response (complete or partial);   Distribution of overall survival
2 Recruiting Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Conditions: Cervical Squamous Cell Carcinoma;   Adenosquamous Carcinoma;   Adenocarcinoma;   Locally Advanced Malignant Neoplasm;   Cervical Cancer
Interventions: Procedure: Extraperitoneal laparoscopic lymphadenectomy (EPLND);   Radiation: Chemoradiation
Outcome Measure: Three Year Overall Survival Rate
3 Recruiting Autologous Young Tumor-Infiltrating Lymphocytes (TIL) From People With Non-Small Cell Lung Cancer Following Preparative Chemotherapy
Conditions: Metastatic Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young TIL
Outcome Measure: Determine the rate of tumor regression
4 Recruiting Hybrid PET/MR in the Therapy of Cervical Cancer
Conditions: Cervix Carcinoma;   Cervical Squamous Cell Carcinoma;   Cervical Adenosquamous Carcinoma
Intervention:
Outcome Measures: Proportion of patients who successfully complete PET/MR scans at all study time-points;   Sensitivity of PET/MR for baseline disease assessment;   Specificity of hybrid PET/MR for baseline disease assessment;   Accuracy of hybrid PET/MR for baseline disease assessment;   Detection of disease with PET/MR at each time point
5 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: quality-of-life assessment
Outcome Measures: Overall survival rate;   Progression-free survival rate;   Rate of acute and long-term toxicities;   Patterns of disease recurrence;   Radiation protocol compliance;   Quality of life including psychosexual health
6 Recruiting Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Biological: ipilimumab;   Other: laboratory biomarker analysis
Outcome Measures: DLTs occurring during adjuvant ipilimumab in the dose escalation phase;   DLTs occurring in the feasibility phase;   Toxicities as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4;   Response rate in patients enrolled with measurable disease assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;   Progression-free survival;   Overall survival;   Location of recurrence (loco-regional versus distant);   Chronic toxicities experienced within one year of completion of therapy
7 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Conditions: Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Response rate using RECIST version 1.1;   Progression-free survival;   Baseline molecular status of archival tumor (c-met amplification & mutation status);   Pharmacodynamic responses in levels of soluble, circulating angiogenic factors
8 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
Outcome Measures: RFS;   OS;   Local control;   Site(s) of recurrence;   Incidence of adverse events graded according to the active version of CTCAE;   Patient risk-benefit;   Treatment compliance;   Quality of life, assessed using the FACT-Cx TOI, FACT-GOG/neurotoxicity 4 subscale, and the Brief Pain Inventory (BPI)
9 Recruiting Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Drug: veliparib;   Other: immunohistochemistry staining method;   Other: diagnostic laboratory biomarker analysis;   Drug: cisplatin;   Drug: paclitaxel
Outcome Measures: Dose-limiting toxicities in the first course of treatment (phase I);   Frequency and severity of adverse effects as assessed by NCI CTCAE v. 4.0;   Objective tumor response (complete or partial response) (phase II);   Progression-free survival (phase II);   Overall survival (phase II)
10 Recruiting MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: diffusion-weighted magnetic resonance imaging;   Procedure: magnetic resonance spectroscopic imaging;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
Outcome Measures: Predictive power of the MRI and PET/CT parameters;   Local control;   Distant metastatic rate;   Disease-free survival
11 Recruiting Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage II Vaginal Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Vaginal Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma
Interventions: Drug: triapine;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: laboratory biomarker analysis
Outcome Measures: 18F-FDG PET/CT metabolic complete response by European Organization for Research and Treatment of Cancer criteria;   Acute (less than 30 day) adverse events, graded according to National Cancer Institute (NCI) CTCAE, version 4;   Late (greater than or equal to 30 day) adverse events, graded according to NCI CTCAE v4.0;   Clinical response as measured by RECIST version 1.1;   Progression-free survival;   Methemoglobin percentage after triapine infusion (Optional)
12 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Radiation: brachytherapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cisplatin
Outcome Measures: Duration of progression-free survival;   Duration of overall survival;   Frequency and severity of adverse effects assessed by Common Terminology Criteria for Adverse Events version 3.0
13 Recruiting Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Lymphedema;   Sexuality and Reproductive Issues;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer
Interventions: Procedure: quality-of-life assessment;   Other: questionnaire administration;   Procedure: cone biopsy;   Procedure: loop electrosurgical excision procedure
Outcome Measures: Change in bladder and bowel function score based on supplemental bladder and bowel (SBB) questions plus 4 items from the FACT-Cx (3 bladder and 1 bowel question);   Change in sexual function and activity based on FSFI (19 items) score plus 2 PROMIS screener items;   Lymphedema based on CLQ score;   Maximum grade and duration of severe adverse events associated with bladder, bowel, and sexual dysfunction and lymphedema (LE) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Maximum grade of treatment-related adverse events according to CTCAE v 4.0;   Change in overall QOL based on FACT-Cx (15 items) score;   Change in cancer worries based on IES score;   Change in reproductive concerns based on RCS (14 items) score;   Site of first recurrence, classified as either local (pelvis regions, including vaginal) or distant (abdomen, lung, bone, brain, and other);   Recurrence-free survival;   Overall survival
14 Recruiting Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: dasatinib;   Drug: paclitaxel;   Drug: carboplatin;   Other: laboratory biomarker analysis
Outcome Measures: Change in EphA2 expression;   Response rate (complete [CR] or partial response [PR]) according to RECIST v. 1.1;   PFS;   OS;   Numbers of CTCs;   Incidence of adverse events as assessed by CTCAE v. 4
15 Recruiting PKCi & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer
Conditions: Adenosquamous Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sirolimus;   Drug: auranofin
Outcome Measures: Progression-free survival rate measured by survival out to 4 months.;   Survival time in this population in comparison to recent historical controls (exemplified by survival of the squamous histology cohort of the Scagliotti et al trial of cisplatin with pemetrexed or gemcitabine for advanced NSCLC).;   Overall response rate (CR or PR);   Adverse Events (AE) profile and safety of the regimen using the CTCAE v4.0.
16 Recruiting Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: external beam radiation therapy;   Radiation: image-guided adaptive radiation therapy;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
Outcome Measures: Local-regional, progression-free (LRPF) rate (RTOG);   Relative change in SUV peak from the baseline to the during-treatment FDG-PET/CT to LRPF (ACRIN);   Time to local-regional progression (TTLRP) (RTOG);   Overall survival (OS) (RTOG);   Progression-free survival (PFS) (RTOG);   Lung cancer cause-specific survival (RTOG);   Radiation-induced lung toxicity (RILT) (RTOG);   Incidence of grade 3+ esophagitis or cardiac adverse events related to chemoradiation between a conventional RT plan and a PET/CT-guided adaptive RT plan, as measured by Common Terminology Criteria for Adverse Events (CTCAE), v. 4 (RTOG);   Baseline FMISO uptake (tumor-to-blood pool ratio) association with LRPF (i.e. the assessment of using baseline FMISO-PET uptake as a prognostic marker) (ACRIN);   Relative change in SUV peak from the baseline to the during-treatment FDG PET/CT and/or the baseline FMISO uptake (tumor-to-blood pool ratio) prediction of the differential benefit of the adaptive therapy (ACRIN);   Change of peak SUVs for FDG from pre- to during-treatment (ACRIN);   Max SUV or change of max SUVs for FDG from pre- to during-treatment (ACRIN);   Change in metabolic tumor volume (ACRIN);   FMISO total hypoxic volume (ACRIN);   FMISO tumor-to-blood pool ratio (ACRIN);   Prediction of OS, LRPF, and lung cancer cause-specific (LCS) survival (ACRIN);   Optimal threshold for differentiating responders from non-responders (ACRIN)
17 Not yet recruiting Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: volumetric-modulated arc therapy;   Drug: metformin hydrochloride;   Other: laboratory biomarker analysis
Outcome Measures: Progression Free Survival (PFS);   Overall Survival (OS);   Time to Local Regional Progression (LRP);   Time to Disease Metastasis (DM);   Rate of treatment-related adverse events using National Cancer Institution (NCI) CTCAE, v. 4
18 Recruiting Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: hypofractionated radiation therapy;   Other: laboratory biomarker analysis;   Radiation: image-guided radiation therapy;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: stereotactic body radiation therapy
Outcome Measures: To determine the maximal tolerated dose using hypofractionated radiotherapy in patients with stage II-III non small cell lung cancer.;   To determine tumor Local control;   To determine Lung cancer Disease specific survival;   Overall survival
19 Not yet recruiting Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Dietary Supplement: soy isoflavones;   Drug: cisplatin;   Drug: etoposide;   Drug: pemetrexed disodium;   Radiation: radiation therapy
Outcome Measures: Safety, in terms of dose-limiting toxicity of adding oral soy isoflavone supplementation to concurrent chemotherapy and radiotherapy, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4;   Survival proportion;   Grade 3-4 toxicity rate graded according to NCI CTCAE version 4.0;   Response (complete response [CR] and partial response [PR]) rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;   Time to tumor progression (TTP);   Overall survival (OS);   Response duration
20 Recruiting Outcome of Women With Cervical Cancer
Condition: Cervical Cancer
Intervention:
Outcome Measure: Outcome of women with cervical cancer

These studies may lead to new treatments and are adding insight into Adenosquamous etiology and treatment.

A major focus of Adenosquamous research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Adenosquamous